Capricor Therapeutics Shares Surge 6.6% on Positive Outlook

Analysts Remain Bullish on Biotech Firm's Promising Pipeline

Apr. 2, 2026 at 5:28pm

Got story updates? Submit your updates here. ›

Shares of Capricor Therapeutics (NASDAQ:CAPR) jumped 6.6% on Thursday, trading as high as $32.12 as the biotech firm continues to gain momentum with its pipeline of cell and exosome-based therapies for cardiovascular and rare diseases.

Why it matters

Capricor's lead candidate, CAP-1002, is being evaluated for treating conditions like Duchenne muscular dystrophy and COVID-19-related heart injury, positioning the company well in high-demand therapeutic areas. The stock's surge reflects growing investor optimism around Capricor's prospects.

The details

The trading volume of 184,252 shares was down 87% from Capricor's average daily volume, indicating strong institutional interest in the stock. Wall Street analysts remain bullish, with a consensus 'Moderate Buy' rating and an average price target of $46.09, suggesting further upside potential.

  • Capricor Therapeutics shares closed at $30.12 on the previous trading day.
  • The stock traded as high as $31.02 and closed at $32.12 on Thursday.

The players

Capricor Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing cell and exosome-based therapies for cardiovascular and rare diseases.

Wall Street Analysts

Equity research analysts covering Capricor Therapeutics, who have issued a consensus 'Moderate Buy' rating on the stock.

Got photos? Submit your photos here. ›

What they’re saying

“Capricor Therapeutics has a promising pipeline of therapies that could address significant unmet medical needs, driving strong investor interest in the stock.”

— Analyst

What’s next

Investors will be closely watching for updates on Capricor's clinical trials and regulatory milestones, which could further catalyze the stock's performance.

The takeaway

Capricor Therapeutics' surge reflects the market's optimism around the company's innovative approach to developing cell and exosome-based therapies for critical medical conditions. As the biotech firm continues to advance its pipeline, it could emerge as a leader in the rapidly evolving field of regenerative medicine.